{"protocolSection":{"identificationModule":{"nctId":"NCT00095199","orgStudyIdInfo":{"id":"13423"},"secondaryIdInfos":[{"id":"I4E-MC-JXBC","type":"OTHER","domain":"Eli Lilly and Company"},{"id":"CP02-0452","type":"OTHER","domain":"ImClone"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer","officialTitle":"Randomized Phase III Study of Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer After Platinum-Based Therapy"},"statusModule":{"statusVerifiedDate":"2012-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2005-01"},"primaryCompletionDateStruct":{"date":"2011-07","type":"ACTUAL"},"completionDateStruct":{"date":"2011-07","type":"ACTUAL"},"studyFirstSubmitDate":"2004-11-01","studyFirstSubmitQcDate":"2004-11-01","studyFirstPostDateStruct":{"date":"2004-11-02","type":"ESTIMATED"},"resultsFirstSubmitDate":"2012-06-19","resultsFirstSubmitQcDate":"2012-09-13","resultsFirstPostDateStruct":{"date":"2012-10-15","type":"ESTIMATED"},"lastUpdateSubmitDate":"2012-09-13","lastUpdatePostDateStruct":{"date":"2012-10-15","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This trial is a multicenter, open-label, randomized, Phase III study in patients with recurrent or progressive Non-Small Cell Lung Cancer (NSCLC) after failure of an initial platinum-based chemotherapy. Patients will receive either Docetaxel or Pemetrexed as chemotherapy at the investigator's choice. Within each chemotherapy group, patients will be randomized to receive Cetuximab plus chemotherapy or chemotherapy alone (Cetuximab \\& Pemetrexed or Pemetrexed alone; Cetuximab \\& Docetaxel or Docetaxel alone)."},"conditionsModule":{"conditions":["Non Small Cell Lung Cancer"],"keywords":["Recurrent or Progressive Non-Small Cell Lung Cancer","Second-line therapy","Docetaxel","Pemetrexed","Cetuximab","Failed platinum-based therapy","NSCLC"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":939,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cetuximab & Pemetrexed","type":"EXPERIMENTAL","interventionNames":["Drug: Pemetrexed","Biological: Cetuximab"]},{"label":"Pemetrexed","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Pemetrexed"]},{"label":"Cetuximab & Docetaxel","type":"EXPERIMENTAL","interventionNames":["Biological: Cetuximab","Drug: Docetaxel"]},{"label":"Docetaxel","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Docetaxel"]}],"interventions":[{"type":"DRUG","name":"Pemetrexed","description":"Pemetrexed 500 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.","armGroupLabels":["Cetuximab & Pemetrexed","Pemetrexed"],"otherNames":["Alimta","LY231514"]},{"type":"BIOLOGICAL","name":"Cetuximab","description":"Cetuximab 400/250 mg/m\\^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity.","armGroupLabels":["Cetuximab & Docetaxel","Cetuximab & Pemetrexed"],"otherNames":["Erbitux","LY2939777"]},{"type":"DRUG","name":"Docetaxel","description":"Docetaxel 75 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.","armGroupLabels":["Cetuximab & Docetaxel","Docetaxel"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression Free Survival (PFS)","description":"PFS was defined as the time from randomization until the date of progressive disease (PD) or death from any cause. Participants who were alive and without progression were censored at the date of their last tumor assessment. PFS was assessed by the independent review committee (IRC) in the Pemetrexed group (Cetuximab \\& Pemetrexed versus Pemetrexed) and by the investigator in the Docetaxel group (Cetuximab \\& Docetaxel versus Docetaxel).","timeFrame":"Randomization to progression of disease or death due to any cause up to 59.6 months"}],"secondaryOutcomes":[{"measure":"Overall Survival (OS)","description":"OS was defined as the time from randomization to death. Participants without a date of death were censored on the last date participants were known to be alive, or lost to follow-up.","timeFrame":"Randomization to the date of death from any cause up to 72.8 months"},{"measure":"Proportion of Randomized Participants With the Best Overall Response (OR) of Partial Response (PR) or Complete Response (CR) (Overall Response Rate [ORR])","description":"The best overall response rate (ORR) was the proportion of randomized participants with a best OR of CR or PR, according to modified World Health Organization (WHO) guidelines. It was calculated as the total number of participants with CR or PR divided by the total number of participants treated in that arm. Participants with no post-baseline evaluation were considered as non-responders. The tumor response was assessed by the independent review committee (IRC) in the Pemetrexed group and by the investigator in the Docetaxel group.","timeFrame":"Randomization until progression of disease or death from any cause up to 59.6 months"},{"measure":"Proportion of Randomized Participants With Best Overall Response (OR) of Partial Response (PR), Complete Response (CR), or Stable Disease (SD)","description":"The disease control rate (DCR) was the proportion of randomized participants with a best OR of CR, PR or SD according to modified World Health Organization (WHO) guidelines. It was calculated as the total number of participants with CR, PR or SD divided by the total number of participants randomized in that arm. The tumor response was assessed by the independent review committee (IRC) in the Pemetrexed group and by the investigator in the Docetaxel group.","timeFrame":"Randomization to progression of disease or death due to any cause up to 59.6 months"},{"measure":"Percentage of Participants With Symptomatic Response (Symptom Response Rates) Using the Lung Cancer Subscale (LCS) Scores of Functional Assessment of Cancer Therapy for Participants With Lung Cancer (FACT-L)","description":"The FACT-LCS is a set of 7 questions to inventory problems specific to lung cancer symptoms. Participants rate each item on a 5-point Likert-type scale from 0 (not at all) to 4 (very much). Scores range from 0-28 and higher score indicates fewer symptoms. Symptom response (improvement) was defined as ≥2 point increase from baseline in the 7-item LCS score that was maintained for 2 consecutive assessments at least 3 weeks, and not \\>5 weeks apart for participants, whose baseline LCS score was ≤26. Symptom response rate was the percentage of participants with symptomatic response.","timeFrame":"At baseline, every 3 weeks and 30 days after end of therapy up to 50 months"},{"measure":"Time to Symptomatic Progression","description":"The FACT-LCS (see description in Outcome measure 5) inventories problems specific to lung cancer symptoms. Using this Scale, Symptom progression = a ≥ 2 point decrease from baseline in LCS score maintained for 2 consecutive assessments ≥3 weeks, and \\<5 weeks, apart. The symptom progression date = the first of 2 consecutive assessments with a ≥2 point decline. Time to symptomatic progression = the time from randomization to the symptom progression date. For participants with no symptom progression, time to symptomatic progression was censored the date of last symptom assessment.","timeFrame":"Randomization until symptomatic progression up to 48.3 months"},{"measure":"Duration of Overall Response (OR)","description":"The duration of response, in participants with best OR of complete response (CR) or partial response (PR), was measured from the date criteria are met for CR/PR (not confirmation date, whichever was first recorded), until the first occurrence date that the criteria of progressive disease (PD) was met, or death. Participants who were alive and without progression were censored at the date of their last independent review committee (IRC) tumor assessment. The tumor response and progression were assessed by the IRC in the Pemetrexed group and by the investigator in the Docetaxel group.","timeFrame":"Time of first occurrence of either (PR) or (CR) to the first date of progressive disease or death up to 32.5 months"},{"measure":"Number of Participants With Common Toxicity Criteria (CTC) Grade 3 or 4 Toxicities","description":"National Cancer Institutes-Common Toxicity Criteria version 3.0 was used by investigators to assess participant toxicities. Mapping of investigator verbatim terms to CTCAE terms was done by the sponsor/designee using CTCAE v4.0. Participants reported had grade 3 or 4 toxicities (or both potentially). Grade 3 AEs: severe or medically significant but not immediately life-threatening;hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 AEs: life-threatening consequences; urgent intervention indicated.","timeFrame":"Time from first dose to 30 days after last dose of study therapy up to 28.3 months for Cetuximab & Pemetrexed (versus Pemetrexed alone) and up to 54.3 months for Cetuximab + Docetaxel (versus Docetaxel alone)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pathologic confirmation of metastatic, unresectable, or locally-advanced NSCLC.\n* Disease progression during or following one prior platinum-based chemotherapy regimen for advanced disease (stage IIIB or IV).\n* Bidimensionally measurable disease.\n* Karnofsky performance status score of 60 to 100 at study entry.\n* The participant has tumor tissue available for immunohistochemical determination of epidermal growth factor (EGFR) expression.\n* Adequate recovery from recent surgery, chemotherapy, and radiation therapy. At least 4 weeks must have elapsed from major surgery, prior chemotherapy, prior treatment with an investigational agent, or prior radiation therapy (palliative radiation therapy is allowed).\n* Accessible for treatment and follow-up. Participants enrolled in this trial must be treated at the participating center.\n* Women of childbearing potential (WOCBP) and fertile men with partners of childbearing potential must be using an adequate method of contraception.\n* WOCBP must have a negative serum or urine pregnancy test.\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding.\n* Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.\n* A serious uncontrolled medical disorder that would impair the ability of the patient to receive protocol therapy.\n* Symptomatic or uncontrolled metastases in the brain. Participants receiving a glucocorticoid for brain metastases will be excluded, but those receiving anticonvulsants will be eligible.\n* Uncontrolled pleural effusion or ascites.\n* Peripheral neuropathy greater than grade 2, as assessed by the National Cancer Institutes-Common Toxicity Criteria Adverse Events (NCI-CTCAE), Version 3.0.\n* Any concurrent malignancy other than basal cell skin cancer, or carcinoma in situ of the cervix. Patients with a previous malignancy, but without evidence of disease for greater than or equal 3 years will be allowed to enter the trial.\n* More than one prior chemotherapy regimen for advanced disease.\n* Inadequate hematologic function defined by an absolute neutrophil count (ANC) \\<1,500/mm3, a platelet count \\<100,000/mm3, and a hemoglobin level \\<9 g/dL. Red blood cell transfusions are not permitted within 7 days of receiving cetuximab, docetaxel, or pemetrexed.\n* Inadequate hepatic function, defined by a total bilirubin level \\>1.5 times the upper limit of normal (ULN), aspartate transaminase (AST) and alanine aminotransferase (ALT) levels \\>2.5 times the ULN (greater than or equal to 5 times the ULN if known liver metastases), and an alkaline phosphatase level \\>5.0 times the ULN.\n* Inadequate renal function defined by a serum creatinine level \\>1.5 times the ULN.\n* Prior treatment with cetuximab, or any other epidermal growth factor receptor inhibitors, including tyrosine kinase inhibitors, such as gefitinib or erlotinib. Participants must not have received prior chimerized or murine monoclonal antibody therapy. Prior treatment with other monoclonal antibodies targeting receptors other than the EGFR is permitted \\>30 days prior to randomization.\n* Prior treatment with docetaxel or pemetrexed therapy.\n* Inability or unwillingness to take folic acid or vitamin B12 supplementation.\n* Inability or unwillingness to interrupt nonsteroidal anti-inflammatory drugs (NSAIDs) for a 5-day period (8-day period for long-acting agents such as piroxicam). Aspirin will be permitted during the study.\n* Patients (including prisoners) who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (eg, infectious disease) illness.\n* Prior treatment with an experimental drug or medical device within 30 days of randomization.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Birmingham","state":"Alabama","zip":"35294","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Montgomery","state":"Alabama","zip":"36106","country":"United States","geoPoint":{"lat":32.36681,"lon":-86.29997}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Phoenix","state":"Arizona","zip":"85012","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tucson","state":"Arizona","zip":"85715","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tuscon","state":"Arizona","zip":"85704","country":"United States"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Greenbrae","state":"California","zip":"94904","country":"United States","geoPoint":{"lat":37.94854,"lon":-122.5247}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"La Jolla","state":"California","zip":"92093","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Denver","state":"Colorado","zip":"80218","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Stamford","state":"Connecticut","zip":"06902","country":"United States","geoPoint":{"lat":41.05343,"lon":-73.53873}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Trumbull","state":"Connecticut","zip":"06611","country":"United States","geoPoint":{"lat":41.24287,"lon":-73.20067}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Jacksonville","state":"Florida","zip":"32256","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lake Worth","state":"Florida","zip":"33461","country":"United States","geoPoint":{"lat":26.61708,"lon":-80.07231}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"West Palm Beach","state":"Florida","zip":"33401","country":"United States","geoPoint":{"lat":26.71534,"lon":-80.05337}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Athens","state":"Georgia","zip":"30607","country":"United States","geoPoint":{"lat":33.96095,"lon":-83.37794}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Atlanta","state":"Georgia","zip":"30341","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Augusta","state":"Georgia","zip":"30901","country":"United States","geoPoint":{"lat":33.47097,"lon":-81.97484}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Chicago","state":"Illinois","zip":"60674","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Indianapolis","state":"Indiana","zip":"46227","country":"United States","geoPoint":{"lat":39.76838,"lon":-86.15804}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Overland Park","state":"Kansas","zip":"66210","country":"United States","geoPoint":{"lat":38.98223,"lon":-94.67079}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Wichita","state":"Kansas","zip":"67214","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Metairie","state":"Louisiana","zip":"70006","country":"United States","geoPoint":{"lat":29.98409,"lon":-90.15285}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bethesda","state":"Maryland","zip":"20817","country":"United States","geoPoint":{"lat":38.98067,"lon":-77.10026}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Frederick","state":"Maryland","zip":"21701","country":"United States","geoPoint":{"lat":39.41427,"lon":-77.41054}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kalamazoo","state":"Michigan","zip":"49048","country":"United States","geoPoint":{"lat":42.29171,"lon":-85.58723}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mount Clemens","state":"Michigan","zip":"48043","country":"United States","geoPoint":{"lat":42.59726,"lon":-82.87798}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Minneapolis","state":"Minnesota","zip":"55404","country":"United States","geoPoint":{"lat":44.97997,"lon":-93.26384}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Saint Louis Park","state":"Minnesota","zip":"55416","country":"United States","geoPoint":{"lat":44.9483,"lon":-93.34801}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Saint Joseph","state":"Missouri","zip":"64507","country":"United States","geoPoint":{"lat":39.76861,"lon":-94.84663}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Billings","state":"Montana","zip":"59101","country":"United States","geoPoint":{"lat":45.78329,"lon":-108.50069}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Las Vegas","state":"Nevada","zip":"89169","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cherry Hill","state":"New Jersey","zip":"08003","country":"United States","geoPoint":{"lat":39.93484,"lon":-75.03073}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Albany","state":"New York","zip":"12208","country":"United States","geoPoint":{"lat":42.65258,"lon":-73.75623}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Rochester","state":"New York","zip":"14623","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cary","state":"North Carolina","zip":"27518","country":"United States","geoPoint":{"lat":35.79154,"lon":-78.78112}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Concord","state":"North Carolina","zip":"28025","country":"United States","geoPoint":{"lat":35.40888,"lon":-80.58158}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"High Point","state":"North Carolina","zip":"27262","country":"United States","geoPoint":{"lat":35.95569,"lon":-80.00532}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cincinnati","state":"Ohio","zip":"45267","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Columbus","state":"Ohio","zip":"43215","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tulsa","state":"Oklahoma","zip":"74136","country":"United States","geoPoint":{"lat":36.15398,"lon":-95.99277}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Eugene","state":"Oregon","zip":"97401","country":"United States","geoPoint":{"lat":44.05207,"lon":-123.08675}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Portland","state":"Oregon","zip":"97239","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Dunmore","state":"Pennsylvania","zip":"18512","country":"United States","geoPoint":{"lat":41.4198,"lon":-75.63241}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kingston","state":"Pennsylvania","zip":"18704","country":"United States","geoPoint":{"lat":41.26175,"lon":-75.89686}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Philadelphia","state":"Pennsylvania","zip":"19114","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Greenville","state":"South Carolina","zip":"29605","country":"United States","geoPoint":{"lat":34.85262,"lon":-82.39401}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hilton Head Island","state":"South Carolina","zip":"29926","country":"United States","geoPoint":{"lat":32.19382,"lon":-80.73816}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mt. Pleasant","state":"South Carolina","zip":"29464","country":"United States","geoPoint":{"lat":32.79407,"lon":-79.86259}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Memphis","state":"Tennessee","zip":"38138","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bedford","state":"Texas","zip":"76022","country":"United States","geoPoint":{"lat":32.84402,"lon":-97.14307}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Dallas","state":"Texas","zip":"75246","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Grapevine","state":"Texas","zip":"76051","country":"United States","geoPoint":{"lat":32.93429,"lon":-97.07807}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mesquite","state":"Texas","zip":"75150","country":"United States","geoPoint":{"lat":32.7668,"lon":-96.59916}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Sugar Land","state":"Texas","zip":"77479","country":"United States","geoPoint":{"lat":29.61968,"lon":-95.63495}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tyler","state":"Texas","zip":"75702","country":"United States","geoPoint":{"lat":32.35126,"lon":-95.30106}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Salt Lake City","state":"Utah","zip":"84106","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Colchester","state":"Vermont","zip":"05446","country":"United States","geoPoint":{"lat":44.54394,"lon":-73.14791}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Norfolk","state":"Virginia","zip":"23502","country":"United States","geoPoint":{"lat":36.84681,"lon":-76.28522}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Richmond","state":"Virginia","zip":"23249","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Seattle","state":"Washington","zip":"98133","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Vancouver","state":"Washington","zip":"98684","country":"United States","geoPoint":{"lat":45.63873,"lon":-122.66149}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Calgary","state":"Alberta","zip":"T2N 4N2","country":"Canada","geoPoint":{"lat":51.05011,"lon":-114.08529}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Vancouver","state":"British Columbia","zip":"V5Z 4E6","country":"Canada","geoPoint":{"lat":49.24966,"lon":-123.11934}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ottawa","state":"Ontario","zip":"K1H 8L6","country":"Canada","geoPoint":{"lat":45.41117,"lon":-75.69812}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Montreal","state":"Quebec","zip":"H2L 4M1","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Saint-Jérôme","state":"Quebec","zip":"J7Z 5T3","country":"Canada","geoPoint":{"lat":45.78036,"lon":-74.00365}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Sainte-Foy","state":"Quebec","zip":"G1V 4G2","country":"Canada","geoPoint":{"lat":46.78139,"lon":-71.29217}}]},"referencesModule":{"references":[{"pmid":"24231627","type":"DERIVED","citation":"Kim ES, Neubauer M, Cohn A, Schwartzberg L, Garbo L, Caton J, Robert F, Reynolds C, Katz T, Chittoor S, Simms L, Saxman S. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol. 2013 Dec;14(13):1326-36. doi: 10.1016/S1470-2045(13)70473-X. Epub 2013 Nov 12."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Although 939 participants were initially randomized, 1 participant's data was inadvertently lost by a site prior to being entered into the database. As a result, we are reporting 938 as randomized.","groups":[{"id":"FG000","title":"Cetuximab & Pemetrexed","description":"Cetuximab 400/250 mg/m\\^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles, until disease progression or unacceptable toxicity. Pemetrexed 500 mg/m\\^2 administered intravenously on day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles."},{"id":"FG001","title":"Pemetrexed","description":"Pemetrexed 500 mg/m\\^2 administered intravenously on Day 1 of 3 week cycle for up to six (3-week) cycles."},{"id":"FG002","title":"Cetuximab and Docetaxel","description":"Cetuximab 400/250 mg/m\\^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity. Docetaxel 75 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."},{"id":"FG003","title":"Docetaxel","description":"Docetaxel 75 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"1 participant has no data in database; not included in analyses. Data was lost/destroyed at site.","numSubjects":"302"},{"groupId":"FG001","numSubjects":"304"},{"groupId":"FG002","numSubjects":"167"},{"groupId":"FG003","numSubjects":"166"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"62"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"23"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"296"},{"groupId":"FG001","numSubjects":"242"},{"groupId":"FG002","numSubjects":"160"},{"groupId":"FG003","numSubjects":"143"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"22"},{"groupId":"FG002","numSubjects":"26"},{"groupId":"FG003","numSubjects":"11"}]},{"type":"Progressive disease","reasons":[{"groupId":"FG000","numSubjects":"213"},{"groupId":"FG001","numSubjects":"179"},{"groupId":"FG002","numSubjects":"105"},{"groupId":"FG003","numSubjects":"98"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"11"},{"groupId":"FG003","numSubjects":"9"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"21"},{"groupId":"FG001","numSubjects":"16"},{"groupId":"FG002","numSubjects":"13"},{"groupId":"FG003","numSubjects":"22"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Liver function test results elevated","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Surgery needed could not start in 7 days","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Not eligible","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Started Palliative Radiotherapy","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Started radiotherapy regimen","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Primary tumor removed in other surgery","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Data inadvertently lost by site","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Cetuximab & Pemetrexed","description":"Cetuximab 400/250 mg/m\\^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity. Pemetrexed 500 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles."},{"id":"BG001","title":"Pemetrexed","description":"Pemetrexed 500 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles."},{"id":"BG002","title":"Cetuximab & Docetaxel","description":"Cetuximab 400/250 mg/m\\^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity. Docetaxel 75 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."},{"id":"BG003","title":"Docetaxel","description":"Docetaxel 75 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"301"},{"groupId":"BG001","value":"304"},{"groupId":"BG002","value":"167"},{"groupId":"BG003","value":"166"},{"groupId":"BG004","value":"938"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"62.8","spread":"10.0"},{"groupId":"BG001","value":"64.0","spread":"9.4"},{"groupId":"BG002","value":"63.6","spread":"9.4"},{"groupId":"BG003","value":"63.9","spread":"9.2"},{"groupId":"BG004","value":"63.5","spread":"9.5"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"128"},{"groupId":"BG001","value":"116"},{"groupId":"BG002","value":"75"},{"groupId":"BG003","value":"73"},{"groupId":"BG004","value":"392"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"173"},{"groupId":"BG001","value":"188"},{"groupId":"BG002","value":"92"},{"groupId":"BG003","value":"93"},{"groupId":"BG004","value":"546"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"268"},{"groupId":"BG001","value":"265"},{"groupId":"BG002","value":"146"},{"groupId":"BG003","value":"141"},{"groupId":"BG004","value":"820"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"82"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"16"}]}]},{"title":"Hispanic","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"16"}]}]},{"title":"Unknown or Not Reported","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"4"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"265"},{"groupId":"BG001","value":"270"},{"groupId":"BG002","value":"152"},{"groupId":"BG003","value":"151"},{"groupId":"BG004","value":"838"}]}]},{"title":"Canada","categories":[{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"15"},{"groupId":"BG004","value":"100"}]}]}]},{"title":"Epidermal growth factor receptor (EGFR) by immunohistochemistry","description":"Immunohistochemical staining intensity of anti-EGFR antibody: Score 0=No staining is observed in membrane; Score +1=Staining in membrane is partial, weak and barely perceptible; Score +2=Staining is weak but is completely observed in membrane; Score +3=Strong complete membrane staining is observed. EGFR positive staining is a potential prognostic factor in non-small cell lung cancer. Presence of EGFR staining was not, however, an inclusion criteria or used to stratify participants in the trial.","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"+1","categories":[{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"19"},{"groupId":"BG004","value":"103"}]}]},{"title":"+2","categories":[{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"26"},{"groupId":"BG003","value":"34"},{"groupId":"BG004","value":"159"}]}]},{"title":"+3","categories":[{"measurements":[{"groupId":"BG000","value":"118"},{"groupId":"BG001","value":"108"},{"groupId":"BG002","value":"72"},{"groupId":"BG003","value":"58"},{"groupId":"BG004","value":"356"}]}]},{"title":"0","categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"75"}]}]},{"title":"Missing","categories":[{"measurements":[{"groupId":"BG000","value":"80"},{"groupId":"BG001","value":"76"},{"groupId":"BG002","value":"44"},{"groupId":"BG003","value":"45"},{"groupId":"BG004","value":"245"}]}]}]},{"title":"Karnofsky Performance Status","description":"Karnofsky performance status was part of eligibility criteria and classifies participants according to their functional impairment. Scores range from 0-100, the lower the score, the worse the survival for most serious illnesses. 100=Normal. No complaints. No evidence of disease; 90=Able to carry on normal activity. Minor signs of disease; 80=Activity with effort. Some signs of disease; 70=Unable to carry on normal activity or to do active work; 60=Requires occasional assistance, but is able to care for most needs; \\<60=Needs increasing assistance, up to a score of 0=death.","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"60","categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"39"}]}]},{"title":"70","categories":[{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"14"},{"groupId":"BG004","value":"105"}]}]},{"title":"80","categories":[{"measurements":[{"groupId":"BG000","value":"103"},{"groupId":"BG001","value":"91"},{"groupId":"BG002","value":"55"},{"groupId":"BG003","value":"57"},{"groupId":"BG004","value":"306"}]}]},{"title":"90","categories":[{"measurements":[{"groupId":"BG000","value":"101"},{"groupId":"BG001","value":"116"},{"groupId":"BG002","value":"74"},{"groupId":"BG003","value":"64"},{"groupId":"BG004","value":"355"}]}]},{"title":"100","categories":[{"measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"47"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"127"}]}]},{"title":"Missing/unknown","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"6"}]}]}]},{"title":"Pathological Diagnosis","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Adenocarcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"161"},{"groupId":"BG001","value":"185"},{"groupId":"BG002","value":"99"},{"groupId":"BG003","value":"83"},{"groupId":"BG004","value":"528"}]}]},{"title":"Large cell carcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"36"}]}]},{"title":"All other non-squamous diagnoses","categories":[{"measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"29"},{"groupId":"BG004","value":"135"}]}]},{"title":"Squamous cell carcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"76"},{"groupId":"BG001","value":"71"},{"groupId":"BG002","value":"41"},{"groupId":"BG003","value":"51"},{"groupId":"BG004","value":"239"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival (PFS)","description":"PFS was defined as the time from randomization until the date of progressive disease (PD) or death from any cause. Participants who were alive and without progression were censored at the date of their last tumor assessment. PFS was assessed by the independent review committee (IRC) in the Pemetrexed group (Cetuximab \\& Pemetrexed versus Pemetrexed) and by the investigator in the Docetaxel group (Cetuximab \\& Docetaxel versus Docetaxel).","populationDescription":"The intent-to-treat population (ITT) included all participants classified according to the treatment arms into which they were randomized, regardless of the actual treatment received. Censored participants: 10 in Cetuximab + Pemetrexed arm; 25 in Pemetrexed arm; 6 in Cetuximab + Docetaxel arm; 16 in Docetaxel arm.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to progression of disease or death due to any cause up to 59.6 months","groups":[{"id":"OG000","title":"Cetuximab & Pemetrexed","description":"Cetuximab 400/250 mg/m\\^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity. Pemetrexed 500 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week cycles)."},{"id":"OG001","title":"Pemetrexed","description":"Pemetrexed 500 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."},{"id":"OG002","title":"Cetuximab & Docetaxel","description":"Cetuximab 400/250 mg/m\\^2 (initial/weekly) administered intravenously every 3 weeks cycle for up to six (3-week) cycles, after 6 cycles participants on the chemotherapy/cetuximab combination may continue cetuximab alone. Docetaxel 75 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."},{"id":"OG003","title":"Docetaxel","description":"Docetaxel 75 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"301"},{"groupId":"OG001","value":"304"},{"groupId":"OG002","value":"167"},{"groupId":"OG003","value":"166"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.89","lowerLimit":"2.69","upperLimit":"3.22"},{"groupId":"OG001","value":"2.76","lowerLimit":"2.53","upperLimit":"3.29"},{"groupId":"OG002","value":"2.37","lowerLimit":"1.61","upperLimit":"2.89"},{"groupId":"OG003","value":"1.54","lowerLimit":"1.45","upperLimit":"2.50"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.756","pValueComment":"The 2-sided unstratified log-rank test was employed at the 5% significance level.","statisticalMethod":"Log Rank","statisticalComment":"Kaplan-Meier method estimated median PFS time. HR was calculated with unstratified Cox proportional hazards model. HR\\<1 favours Cetuximab arm","paramType":"Hazard Ratio (HR)","paramValue":"1.03","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.87","ciUpperLimit":"1.21"},{"groupIds":["OG002","OG003"],"groupDescription":"The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.391","pValueComment":"The 2-sided unstratified log-rank test was employed at the 5% significance level.","statisticalMethod":"Log Rank","statisticalComment":"Kaplan-Meier method estimated median PFS time. HR was calculated with unstratified Cox proportional hazards model. HR\\<1 favours Cetuximab arm","paramType":"Hazard Ratio (HR)","paramValue":"0.91","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.73","ciUpperLimit":"1.13"}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS was defined as the time from randomization to death. Participants without a date of death were censored on the last date participants were known to be alive, or lost to follow-up.","populationDescription":"The intent-to-treat population (ITT) included all participants classified according to the treatment arms into which they were randomized, regardless of the actual treatment received. Censored participants: 24 in Cetuximab + Pemetrexed arm; 43 in Pemetrexed arm; 12 in Cetuximab + Docetaxel arm; 22 in Docetaxel arm.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to the date of death from any cause up to 72.8 months","groups":[{"id":"OG000","title":"Cetuximab & Pemetrexed","description":"Cetuximab 400/250 mg/m\\^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity. Pemetrexed 500 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles."},{"id":"OG001","title":"Pemetrexed","description":"Pemetrexed 500 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."},{"id":"OG002","title":"Cetuximab & Docetaxel","description":"Cetuximab 400/250 mg/m\\^2 (initial/weekly) administered intravenously every 3 weeks cycle for up to six (3-week) cycles, after 6 cycles participants on the chemotherapy/cetuximab combination may continue cetuximab alone. Docetaxel 75 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."},{"id":"OG003","title":"Docetaxel","description":"Docetaxel 75 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"301"},{"groupId":"OG001","value":"304"},{"groupId":"OG002","value":"167"},{"groupId":"OG003","value":"166"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.93","lowerLimit":"6.28","upperLimit":"7.85"},{"groupId":"OG001","value":"7.79","lowerLimit":"6.77","upperLimit":"8.41"},{"groupId":"OG002","value":"5.75","lowerLimit":"4.73","upperLimit":"8.31"},{"groupId":"OG003","value":"8.15","lowerLimit":"6.11","upperLimit":"9.20"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.864","pValueComment":"The 2-sided unstratified log-rank test was employed at the 5% significance level","statisticalMethod":"Log Rank","statisticalComment":"Kaplan-Meier method estimated median OS time. HR was calculated with unstratified Cox proportional hazards model. HR\\<1 favors Cetuximab arm","paramType":"Hazard Ratio (HR)","paramValue":"1.01","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.86","ciUpperLimit":"1.20"},{"groupIds":["OG002","OG003"],"groupDescription":"The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.307","pValueComment":"The 2-sided unstratified log-rank test was employed at the 5% significance level.","statisticalMethod":"Log Rank","statisticalComment":"Kaplan-Meier method estimated median OS time. HR was calculated with unstratified Cox proportional hazards model. HR\\<1 favors Cetuximab arm","paramType":"Hazard Ratio (HR)","paramValue":"1.13","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.90","ciUpperLimit":"1.41"}]},{"type":"SECONDARY","title":"Proportion of Randomized Participants With the Best Overall Response (OR) of Partial Response (PR) or Complete Response (CR) (Overall Response Rate [ORR])","description":"The best overall response rate (ORR) was the proportion of randomized participants with a best OR of CR or PR, according to modified World Health Organization (WHO) guidelines. It was calculated as the total number of participants with CR or PR divided by the total number of participants treated in that arm. Participants with no post-baseline evaluation were considered as non-responders. The tumor response was assessed by the independent review committee (IRC) in the Pemetrexed group and by the investigator in the Docetaxel group.","populationDescription":"The intent-to-treat population (ITT) included all participants classified according to the treatment arms into which they were randomized, regardless of the actual treatment received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"proportion of participants","timeFrame":"Randomization until progression of disease or death from any cause up to 59.6 months","groups":[{"id":"OG000","title":"Cetuximab & Pemetrexed","description":"Cetuximab 400/250 mg/m\\^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity. Pemetrexed 500 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles."},{"id":"OG001","title":"Pemetrexed","description":"Pemetrexed 500 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."},{"id":"OG002","title":"Cetuximab & Docetaxel","description":"Cetuximab 400/250 mg/m\\^2 (initial/weekly) administered intravenously every 3 weeks cycle for up to six (3-week) cycles, after 6 cycles participants on the chemotherapy/cetuximab combination may continue cetuximab alone. Docetaxel 75 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."},{"id":"OG003","title":"Docetaxel","description":"Docetaxel 75 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"301"},{"groupId":"OG001","value":"304"},{"groupId":"OG002","value":"167"},{"groupId":"OG003","value":"166"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.066","lowerLimit":"0.038","upperLimit":"0.095"},{"groupId":"OG001","value":"0.043","lowerLimit":"0.020","upperLimit":"0.066"},{"groupId":"OG002","value":"0.078","lowerLimit":"0.037","upperLimit":"0.118"},{"groupId":"OG003","value":"0.066","lowerLimit":"0.028","upperLimit":"0.104"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.200","pValueComment":"The 2-sided unstratified Mantel Haenszel test was employed at the 5% significance level.","statisticalMethod":"Mantel Haenszel","statisticalComment":"HR\\<1 favors Cetuximab arm","paramType":"Odds Ratio (OR)","paramValue":"1.59","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.78","ciUpperLimit":"3.26"},{"groupIds":["OG002","OG003"],"groupDescription":"The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.683","pValueComment":"The 2-sided unstratified Mantel Haenszel test was employed at the 5% significance level.","statisticalMethod":"Mantel Haenszel","statisticalComment":"HR\\<1 favors Cetuximab arm","paramType":"Odds Ratio (OR)","paramValue":"1.19","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.52","ciUpperLimit":"2.74"}]},{"type":"SECONDARY","title":"Proportion of Randomized Participants With Best Overall Response (OR) of Partial Response (PR), Complete Response (CR), or Stable Disease (SD)","description":"The disease control rate (DCR) was the proportion of randomized participants with a best OR of CR, PR or SD according to modified World Health Organization (WHO) guidelines. It was calculated as the total number of participants with CR, PR or SD divided by the total number of participants randomized in that arm. The tumor response was assessed by the independent review committee (IRC) in the Pemetrexed group and by the investigator in the Docetaxel group.","populationDescription":"The intent-to-treat population (ITT) included all participants classified according to the treatment arms into which they were randomized, regardless of the actual treatment received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"proportion of participants","timeFrame":"Randomization to progression of disease or death due to any cause up to 59.6 months","groups":[{"id":"OG000","title":"Cetuximab & Pemetrexed","description":"Cetuximab 400/250 mg/m\\^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity. Pemetrexed 500 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week cycles)."},{"id":"OG001","title":"Pemetrexed","description":"Pemetrexed 500 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."},{"id":"OG002","title":"Cetuximab & Docetaxel","description":"Cetuximab 400/250 mg/m\\^2 (initial/weekly) administered intravenously every 3 weeks cycle for up to six (3-week) cycles, after 6 cycles participants on the chemotherapy/cetuximab combination may continue cetuximab alone. Docetaxel 75 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."},{"id":"OG003","title":"Docetaxel","description":"Docetaxel 75 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"301"},{"groupId":"OG001","value":"304"},{"groupId":"OG002","value":"167"},{"groupId":"OG003","value":"166"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.522","lowerLimit":"0.465","upperLimit":"0.578"},{"groupId":"OG001","value":"0.480","lowerLimit":"0.424","upperLimit":"0.536"},{"groupId":"OG002","value":"0.335","lowerLimit":"0.264","upperLimit":"0.407"},{"groupId":"OG003","value":"0.253","lowerLimit":"0.187","upperLimit":"0.319"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.310","pValueComment":"The 2-sided unstratified Mantel Haenszel test was employed at the 5% significance level.","statisticalMethod":"Mantel Haenszel","statisticalComment":"HR\\<1 favors Cetuximab arm","paramType":"Odds Ratio (OR)","paramValue":"1.18","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.86","ciUpperLimit":"1.62"},{"groupIds":["OG002","OG003"],"groupDescription":"The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.100","pValueComment":"The 2-sided unstratified Mantel Haenszel test was employed at the 5% significance level.","statisticalMethod":"Mantel Haenszel","statisticalComment":"HR\\<1 favors Cetuximab arm","paramType":"Odds Ratio (OR)","paramValue":"1.49","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.93","ciUpperLimit":"2.40"}]},{"type":"SECONDARY","title":"Percentage of Participants With Symptomatic Response (Symptom Response Rates) Using the Lung Cancer Subscale (LCS) Scores of Functional Assessment of Cancer Therapy for Participants With Lung Cancer (FACT-L)","description":"The FACT-LCS is a set of 7 questions to inventory problems specific to lung cancer symptoms. Participants rate each item on a 5-point Likert-type scale from 0 (not at all) to 4 (very much). Scores range from 0-28 and higher score indicates fewer symptoms. Symptom response (improvement) was defined as ≥2 point increase from baseline in the 7-item LCS score that was maintained for 2 consecutive assessments at least 3 weeks, and not \\>5 weeks apart for participants, whose baseline LCS score was ≤26. Symptom response rate was the percentage of participants with symptomatic response.","populationDescription":"The randomized participants with baseline LCS scores less than or equal to 26.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"At baseline, every 3 weeks and 30 days after end of therapy up to 50 months","groups":[{"id":"OG000","title":"Cetuximab & Pemetrexed","description":"Cetuximab 400/250 mg/m\\^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity. Pemetrexed 500 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles."},{"id":"OG001","title":"Pemetrexed","description":"Pemetrexed 500 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."},{"id":"OG002","title":"Cetuximab & Docetaxel","description":"Cetuximab 400/250 mg/m\\^2 (initial/weekly) administered intravenously every 3 weeks cycle for up to six (3-week) cycles, after 6 cycles participants on the chemotherapy/cetuximab combination may continue cetuximab alone. Docetaxel 75 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."},{"id":"OG003","title":"Docetaxel","description":"Docetaxel 75 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"280"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"150"},{"groupId":"OG003","value":"155"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","lowerLimit":"12.7","upperLimit":"21.6"},{"groupId":"OG001","value":"22.9","lowerLimit":"17.9","upperLimit":"27.8"},{"groupId":"OG002","value":"17.3","lowerLimit":"11.3","upperLimit":"23.4"},{"groupId":"OG003","value":"13.5","lowerLimit":"8.2","upperLimit":"18.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.091","pValueComment":"The 2-sided unstratified Mantel Haenszel test was employed at the 5% significance level.","statisticalMethod":"Mantel Haenszel","statisticalComment":"HR\\<1 favors Cetuximab arm","paramType":"Odds Ratio (OR)","paramValue":"0.70","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.46","ciUpperLimit":"1.06"},{"groupIds":["OG002","OG003"],"groupDescription":"The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.361","pValueComment":"The 2-sided unstratified Mantel Haenszel test was employed at the 5% significance level.","statisticalMethod":"Mantel Haenszel","statisticalComment":"HR\\<1 favors Cetuximab arm","paramType":"Odds Ratio (OR)","paramValue":"1.34","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.72","ciUpperLimit":"2.50"}]},{"type":"SECONDARY","title":"Time to Symptomatic Progression","description":"The FACT-LCS (see description in Outcome measure 5) inventories problems specific to lung cancer symptoms. Using this Scale, Symptom progression = a ≥ 2 point decrease from baseline in LCS score maintained for 2 consecutive assessments ≥3 weeks, and \\<5 weeks, apart. The symptom progression date = the first of 2 consecutive assessments with a ≥2 point decline. Time to symptomatic progression = the time from randomization to the symptom progression date. For participants with no symptom progression, time to symptomatic progression was censored the date of last symptom assessment.","populationDescription":"All randomized participants with a baseline LCS \\>= 2 were included. Censored participants: 237 in Cetuximab plus Pemetrexed arm; 244 in Pemetrexed arm; 126 in Cetuximab plus Docetaxel arm; 131 in Docetaxel arm.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization until symptomatic progression up to 48.3 months","groups":[{"id":"OG000","title":"Cetuximab & Pemetrexed","description":"Cetuximab 400/250 mg/m\\^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity. Pemetrexed 500 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles."},{"id":"OG001","title":"Pemetrexed","description":"Pemetrexed 500 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."},{"id":"OG002","title":"Cetuximab & Docetaxel","description":"Cetuximab 400/250 mg/m\\^2 (initial/weekly) administered intravenously every 3 weeks cycle for up to six (3-week cycles), after 6 cycles participants on the chemotherapy/cetuximab combination may continue cetuximab alone. Docetaxel 75 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."},{"id":"OG003","title":"Docetaxel","description":"Docetaxel 75 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"287"},{"groupId":"OG002","value":"152"},{"groupId":"OG003","value":"158"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"The median time to symptomatic progression is not estimable because the probability of symptomatic progression free never decreased to 0.5"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"The median time to symptomatic progression is not estimable because the probability of symptomatic progression free never decreased to 0.5"},{"groupId":"OG002","value":"NA","lowerLimit":"7.00","upperLimit":"NA","comment":"The median time to symptomatic progression is not estimable because the probability of symptomatic progression free never decreased to 0.5"},{"groupId":"OG003","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"The median time to symptomatic progression is not estimable because the probability of symptomatic progression free never decreased to 0.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.472","pValueComment":"The 2-sided unstratified log-rank test was employed at the 5% significance level.","statisticalMethod":"Log Rank","statisticalComment":"Kaplan-Meier estimated time to symptomatic progression. HR was calculated using unstratified Cox proportional hazards model. HR\\<1 favors Cetuximab arm","paramType":"Hazard Ratio (HR)","paramValue":"1.16","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.77","ciUpperLimit":"1.74"},{"groupIds":["OG002","OG003"],"groupDescription":"The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.272","pValueComment":"The 2-sided unstratified log-rank test was employed at the 5% significance level.","statisticalMethod":"Log Rank","statisticalComment":"Kaplan-Meier estimated time to symptomatic progression. HR was calculated using unstratified Cox proportional hazards model. HR\\<1 favors Cetuximab arm","paramType":"Hazard Ratio (HR)","paramValue":"0.73","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.42","ciUpperLimit":"1.27"}]},{"type":"SECONDARY","title":"Duration of Overall Response (OR)","description":"The duration of response, in participants with best OR of complete response (CR) or partial response (PR), was measured from the date criteria are met for CR/PR (not confirmation date, whichever was first recorded), until the first occurrence date that the criteria of progressive disease (PD) was met, or death. Participants who were alive and without progression were censored at the date of their last independent review committee (IRC) tumor assessment. The tumor response and progression were assessed by the IRC in the Pemetrexed group and by the investigator in the Docetaxel group.","populationDescription":"All randomized participants with a best overall response of CR or PR. Censored participants: 1 in Cetuximab plus Pemetrexed arm; 2 in Pemetrexed arm; 1 in Cetuximab plus Docetaxel arm; 0 in Docetaxel arm.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Time of first occurrence of either (PR) or (CR) to the first date of progressive disease or death up to 32.5 months","groups":[{"id":"OG000","title":"Cetuximab & Pemetrexed","description":"Cetuximab 400/250 mg/m\\^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity. Pemetrexed 500 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week cycles)."},{"id":"OG001","title":"Pemetrexed","description":"Pemetrexed 500 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."},{"id":"OG002","title":"Cetuximab & Docetaxel","description":"Cetuximab 400/250 mg/m2 (initial/weekly) administered intravenously every 3 weeks cycle for up to six (3-week) cycles, after 6 cycles participants on the chemotherapy/cetuximab combination may continue cetuximab alone. Docetaxel 75 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week cycles)."},{"id":"OG003","title":"Docetaxel","description":"Docetaxel 75 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"11"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.17","lowerLimit":"2.92","upperLimit":"5.45"},{"groupId":"OG001","value":"6.93","lowerLimit":"3.98","upperLimit":"16.36"},{"groupId":"OG002","value":"5.36","lowerLimit":"2.73","upperLimit":"6.93"},{"groupId":"OG003","value":"5.39","lowerLimit":"3.12","upperLimit":"7.16"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.236","pValueComment":"The 2-sided unstratified log-rank test was employed at the 5% significance level.","statisticalMethod":"Log Rank","statisticalComment":"The Kaplan-Meier method estimated duration of response. HR was calculated using unstratified Cox proportional hazards model. HR\\<1 favors Cetuximab arm","paramType":"Hazard Ratio (HR)","paramValue":"1.58","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.74","ciUpperLimit":"3.36"},{"groupIds":["OG002","OG003"],"groupDescription":"The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.887","pValueComment":"The 2-sided unstratified log-rank test was employed at the 5% significance level.","statisticalMethod":"Log Rank","statisticalComment":"The Kaplan-Meier method estimated duration of response. HR was calculated using unstratified Cox proportional hazards model. HR\\<1 favors Cetuximab arm","paramType":"Hazard Ratio (HR)","paramValue":"0.96","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.42","ciUpperLimit":"2.18"}]},{"type":"SECONDARY","title":"Number of Participants With Common Toxicity Criteria (CTC) Grade 3 or 4 Toxicities","description":"National Cancer Institutes-Common Toxicity Criteria version 3.0 was used by investigators to assess participant toxicities. Mapping of investigator verbatim terms to CTCAE terms was done by the sponsor/designee using CTCAE v4.0. Participants reported had grade 3 or 4 toxicities (or both potentially). Grade 3 AEs: severe or medically significant but not immediately life-threatening;hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 AEs: life-threatening consequences; urgent intervention indicated.","populationDescription":"All randomized participants receiving at least 1 dose of study drug made up the safety population for this outcome measure. Investigators graded events using CTCAE v3.0. Mapping of investigator verbatim terms for toxicity to CTCAE terms was done by the sponsor/designee using CTCAE v4.0.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Time from first dose to 30 days after last dose of study therapy up to 28.3 months for Cetuximab & Pemetrexed (versus Pemetrexed alone) and up to 54.3 months for Cetuximab + Docetaxel (versus Docetaxel alone)","groups":[{"id":"OG000","title":"Cetuximab & Pemetrexed","description":"Cetuximab 400/250 mg/m\\^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week cycles) until disease progression or unacceptable toxicity. Pemetrexed 500 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles."},{"id":"OG001","title":"Pemetrexed","description":"Pemetrexed 500 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."},{"id":"OG002","title":"Cetuximab + Docetaxel","description":"Cetuximab 400/250 mg/m\\^2 (initial/weekly) administered intravenously on Day 1 of every 3 weeks cycle for up to six (3-week) cycles, after 6 cycles participants on the chemotherapy/cetuximab combination may continue cetuximab alone. Docetaxel 75 mg/m2 administered intravenously on Day 1 of 3 week cycle for up to six (3-week) cycles."},{"id":"OG003","title":"Docetaxel","description":"Docetaxel 75 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"292"},{"groupId":"OG001","value":"289"},{"groupId":"OG002","value":"159"},{"groupId":"OG003","value":"149"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"143"},{"groupId":"OG002","value":"112"},{"groupId":"OG003","value":"97"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Randomization to 30 days after study therapy up to 72.8 months for Cetuximab & Pemetrexed (versus just Pemetrexed) and up to 64.3 months for Cetuximab + Docetaxel (versus just Docetaxel)","eventGroups":[{"id":"EG000","title":"Cetuximab & Pemetrexed","description":"Cetuximab 400/250 mg/m\\^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles, until disease progression or unacceptable toxicity. Pemetrexed 500 mg/m\\^2 administered intravenously on day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.","seriousNumAffected":119,"seriousNumAtRisk":292,"otherNumAffected":289,"otherNumAtRisk":292},{"id":"EG001","title":"Pemetrexed","description":"Pemetrexed 500 mg/m\\^2 administered intravenously on Day 1 of 3 week cycle for up to six (3-week) cycles.","seriousNumAffected":86,"seriousNumAtRisk":289,"otherNumAffected":281,"otherNumAtRisk":289},{"id":"EG002","title":"Cetuximab and Docetaxel","description":"Cetuximab 400/250 mg/m\\^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity. Docetaxel 75 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.","seriousNumAffected":84,"seriousNumAtRisk":159,"otherNumAffected":159,"otherNumAtRisk":159},{"id":"EG003","title":"Docetaxel","description":"Docetaxel 75 mg/m\\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.","seriousNumAffected":60,"seriousNumAtRisk":149,"otherNumAffected":147,"otherNumAtRisk":149}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":292},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":289},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":159},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":149}]},{"term":"Coagulopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":292},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":289},{"groupId":"EG002","numEvents":14,"numAffected":13,"numAtRisk":159},{"groupId":"EG003","numEvents":11,"numAffected":11,"numAtRisk":149}]},{"term":"Hypercoagulation","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":289},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":292},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":289},{"groupId":"EG002","numEvents":11,"numAffected":10,"numAtRisk":159},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":149}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":292},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":292},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":10,"numAtRisk":292},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":7,"numAffected":5,"numAtRisk":149}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Atrial tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":159},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":149}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Left ventricular dysfunction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":292},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":149}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Ventricular fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Ventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":292},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Caecitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":292},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":289},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Diverticular perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Duodenal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Gastric haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Gastritis erosive","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Gastrointestinal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Oesophageal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":292},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":289},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":292},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":289},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":159},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":149}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":159},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":149}]},{"term":"Hypothermia","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Impaired healing","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Multi-organ failure","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":292},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":289},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":292},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":289},{"groupId":"EG002","numEvents":10,"numAffected":10,"numAtRisk":159},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":149}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Systemic inflammatory response syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Abdominal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Bronchopneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Catheter site infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":292},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Cellulitis staphylococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Clostridial infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Empyema","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":149}]},{"term":"Gangrene","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Incision site infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Lobar pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Lung infection pseudomonal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Meningitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Necrotising fasciitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Pelvic abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Peridiverticular abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":149}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":16,"numAtRisk":292},{"groupId":"EG001","numEvents":17,"numAffected":17,"numAtRisk":289},{"groupId":"EG002","numEvents":11,"numAffected":9,"numAtRisk":159},{"groupId":"EG003","numEvents":10,"numAffected":10,"numAtRisk":149}]},{"term":"Pneumonia klebsiella","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Postoperative wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":159},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":149}]},{"term":"Sepsis syndrome","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Staphylococcal bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Staphylococcal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Subcutaneous abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Collapse of lung","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Pneumonitis chemical","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Sternal fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Toxicity to various agents","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Traumatic lung injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Activated partial thromboplastin time prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"International normalised ratio increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":292},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":289},{"groupId":"EG002","numEvents":19,"numAffected":17,"numAtRisk":159},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":149}]},{"term":"Electrolyte imbalance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Failure to thrive","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":149}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Hypovolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Metabolic acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Mobility decreased","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Pain in jaw","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Malignant pleural effusion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Metastases to bone","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Non-small cell lung cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Ovarian cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Ataxia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Brain injury","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Brain stem haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":292},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":289},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Depressed level of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":149}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Dysarthria","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Dyskinesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Hydrocephalus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Partial seizures","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Speech disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":292},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":289},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Disorientation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Drug abuse","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Schizoaffective disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Pollakiuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":289},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Renal pain","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Acute respiratory distress syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Apnoeic attack","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Bronchial haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Bronchospasm","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":292},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":149}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":14,"numAtRisk":292},{"groupId":"EG001","numEvents":14,"numAffected":11,"numAtRisk":289},{"groupId":"EG002","numEvents":13,"numAffected":12,"numAtRisk":159},{"groupId":"EG003","numEvents":8,"numAffected":6,"numAtRisk":149}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":289},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":159},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":149}]},{"term":"Hydropneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Hypercapnia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":292},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":289},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":159},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":149}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":292},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":289},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":159},{"groupId":"EG003","numEvents":10,"numAffected":7,"numAtRisk":149}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":292},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":289},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":159},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":149}]},{"term":"Pulmonary fibrosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Respiratory arrest","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":292},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":292},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":289},{"groupId":"EG002","numEvents":8,"numAffected":7,"numAtRisk":159},{"groupId":"EG003","numEvents":6,"numAffected":3,"numAtRisk":149}]},{"term":"Respiratory tract haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Angioedema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Purpura","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Leg amputation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Pain management","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Ventriculo-peritoneal shunt","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":159},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":149}]},{"term":"Exsanguination","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":159},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":149}]},{"term":"Ischaemic limb pain","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Peripheral ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":90,"numAffected":70,"numAtRisk":292},{"groupId":"EG001","numEvents":93,"numAffected":64,"numAtRisk":289},{"groupId":"EG002","numEvents":75,"numAffected":40,"numAtRisk":159},{"groupId":"EG003","numEvents":48,"numAffected":35,"numAtRisk":149}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":10,"numAtRisk":292},{"groupId":"EG001","numEvents":17,"numAffected":11,"numAtRisk":289},{"groupId":"EG002","numEvents":31,"numAffected":15,"numAtRisk":159},{"groupId":"EG003","numEvents":13,"numAffected":7,"numAtRisk":149}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":51,"numAffected":32,"numAtRisk":292},{"groupId":"EG001","numEvents":58,"numAffected":32,"numAtRisk":289},{"groupId":"EG002","numEvents":121,"numAffected":74,"numAtRisk":159},{"groupId":"EG003","numEvents":95,"numAffected":46,"numAtRisk":149}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":14,"numAtRisk":292},{"groupId":"EG001","numEvents":48,"numAffected":22,"numAtRisk":289},{"groupId":"EG002","numEvents":11,"numAffected":7,"numAtRisk":159},{"groupId":"EG003","numEvents":7,"numAffected":2,"numAtRisk":149}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":13,"numAtRisk":292},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":289},{"groupId":"EG002","numEvents":15,"numAffected":15,"numAtRisk":159},{"groupId":"EG003","numEvents":8,"numAffected":8,"numAtRisk":149}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":20,"numAtRisk":292},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":289},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":159},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":149}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":19,"numAtRisk":292},{"groupId":"EG001","numEvents":19,"numAffected":16,"numAtRisk":289},{"groupId":"EG002","numEvents":16,"numAffected":15,"numAtRisk":159},{"groupId":"EG003","numEvents":7,"numAffected":6,"numAtRisk":149}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":16,"numAtRisk":292},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":289},{"groupId":"EG002","numEvents":9,"numAffected":4,"numAtRisk":159},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":149}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":94,"numAffected":75,"numAtRisk":292},{"groupId":"EG001","numEvents":66,"numAffected":60,"numAtRisk":289},{"groupId":"EG002","numEvents":48,"numAffected":41,"numAtRisk":159},{"groupId":"EG003","numEvents":27,"numAffected":25,"numAtRisk":149}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":108,"numAffected":81,"numAtRisk":292},{"groupId":"EG001","numEvents":38,"numAffected":36,"numAtRisk":289},{"groupId":"EG002","numEvents":91,"numAffected":63,"numAtRisk":159},{"groupId":"EG003","numEvents":28,"numAffected":22,"numAtRisk":149}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":21,"numAtRisk":292},{"groupId":"EG001","numEvents":16,"numAffected":15,"numAtRisk":289},{"groupId":"EG002","numEvents":16,"numAffected":12,"numAtRisk":159},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":149}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":146,"numAffected":112,"numAtRisk":292},{"groupId":"EG001","numEvents":128,"numAffected":89,"numAtRisk":289},{"groupId":"EG002","numEvents":68,"numAffected":53,"numAtRisk":159},{"groupId":"EG003","numEvents":48,"numAffected":38,"numAtRisk":149}]},{"term":"Oral pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":11,"numAtRisk":292},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":289},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":159},{"groupId":"EG003","numEvents":8,"numAffected":7,"numAtRisk":149}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":78,"numAffected":54,"numAtRisk":292},{"groupId":"EG001","numEvents":21,"numAffected":21,"numAtRisk":289},{"groupId":"EG002","numEvents":74,"numAffected":53,"numAtRisk":159},{"groupId":"EG003","numEvents":26,"numAffected":23,"numAtRisk":149}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":83,"numAffected":59,"numAtRisk":292},{"groupId":"EG001","numEvents":54,"numAffected":44,"numAtRisk":289},{"groupId":"EG002","numEvents":32,"numAffected":25,"numAtRisk":159},{"groupId":"EG003","numEvents":22,"numAffected":19,"numAtRisk":149}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":40,"numAffected":37,"numAtRisk":292},{"groupId":"EG001","numEvents":42,"numAffected":33,"numAtRisk":289},{"groupId":"EG002","numEvents":41,"numAffected":29,"numAtRisk":159},{"groupId":"EG003","numEvents":20,"numAffected":15,"numAtRisk":149}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":292},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":289},{"groupId":"EG002","numEvents":12,"numAffected":9,"numAtRisk":159},{"groupId":"EG003","numEvents":16,"numAffected":15,"numAtRisk":149}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":209,"numAffected":158,"numAtRisk":292},{"groupId":"EG001","numEvents":191,"numAffected":133,"numAtRisk":289},{"groupId":"EG002","numEvents":146,"numAffected":88,"numAtRisk":159},{"groupId":"EG003","numEvents":99,"numAffected":74,"numAtRisk":149}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":292},{"groupId":"EG001","numEvents":22,"numAffected":18,"numAtRisk":289},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":159},{"groupId":"EG003","numEvents":9,"numAffected":7,"numAtRisk":149}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":70,"numAffected":51,"numAtRisk":292},{"groupId":"EG001","numEvents":35,"numAffected":32,"numAtRisk":289},{"groupId":"EG002","numEvents":28,"numAffected":23,"numAtRisk":159},{"groupId":"EG003","numEvents":28,"numAffected":27,"numAtRisk":149}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":12,"numAtRisk":292},{"groupId":"EG001","numEvents":15,"numAffected":14,"numAtRisk":289},{"groupId":"EG002","numEvents":12,"numAffected":10,"numAtRisk":159},{"groupId":"EG003","numEvents":12,"numAffected":11,"numAtRisk":149}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":60,"numAffected":46,"numAtRisk":292},{"groupId":"EG001","numEvents":43,"numAffected":37,"numAtRisk":289},{"groupId":"EG002","numEvents":29,"numAffected":22,"numAtRisk":159},{"groupId":"EG003","numEvents":14,"numAffected":14,"numAtRisk":149}]},{"term":"Candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":11,"numAtRisk":292},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":289},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":159},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":149}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":292},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":289},{"groupId":"EG002","numEvents":13,"numAffected":10,"numAtRisk":159},{"groupId":"EG003","numEvents":7,"numAffected":5,"numAtRisk":149}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":15,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":6,"numAffected":3,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":18,"numAtRisk":292},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":289},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":159},{"groupId":"EG003","numEvents":7,"numAffected":6,"numAtRisk":149}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":15,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":159},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":149}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":19,"numAtRisk":292},{"groupId":"EG001","numEvents":15,"numAffected":15,"numAtRisk":289},{"groupId":"EG002","numEvents":20,"numAffected":18,"numAtRisk":159},{"groupId":"EG003","numEvents":8,"numAffected":7,"numAtRisk":149}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":102,"numAffected":86,"numAtRisk":292},{"groupId":"EG001","numEvents":63,"numAffected":58,"numAtRisk":289},{"groupId":"EG002","numEvents":68,"numAffected":54,"numAtRisk":159},{"groupId":"EG003","numEvents":47,"numAffected":45,"numAtRisk":149}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":27,"numAtRisk":292},{"groupId":"EG001","numEvents":21,"numAffected":17,"numAtRisk":289},{"groupId":"EG002","numEvents":28,"numAffected":24,"numAtRisk":159},{"groupId":"EG003","numEvents":26,"numAffected":14,"numAtRisk":149}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":11,"numAtRisk":292},{"groupId":"EG001","numEvents":28,"numAffected":20,"numAtRisk":289},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":159},{"groupId":"EG003","numEvents":6,"numAffected":4,"numAtRisk":149}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":29,"numAtRisk":292},{"groupId":"EG001","numEvents":12,"numAffected":11,"numAtRisk":289},{"groupId":"EG002","numEvents":32,"numAffected":26,"numAtRisk":159},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":149}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":91,"numAffected":57,"numAtRisk":292},{"groupId":"EG001","numEvents":20,"numAffected":17,"numAtRisk":289},{"groupId":"EG002","numEvents":55,"numAffected":36,"numAtRisk":159},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":149}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":16,"numAtRisk":292},{"groupId":"EG001","numEvents":23,"numAffected":22,"numAtRisk":289},{"groupId":"EG002","numEvents":18,"numAffected":14,"numAtRisk":159},{"groupId":"EG003","numEvents":18,"numAffected":17,"numAtRisk":149}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":44,"numAffected":36,"numAtRisk":292},{"groupId":"EG001","numEvents":16,"numAffected":14,"numAtRisk":289},{"groupId":"EG002","numEvents":19,"numAffected":17,"numAtRisk":159},{"groupId":"EG003","numEvents":8,"numAffected":7,"numAtRisk":149}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":10,"numAtRisk":292},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":289},{"groupId":"EG002","numEvents":12,"numAffected":9,"numAtRisk":159},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":149}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":11,"numAtRisk":292},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":289},{"groupId":"EG002","numEvents":11,"numAffected":10,"numAtRisk":159},{"groupId":"EG003","numEvents":7,"numAffected":6,"numAtRisk":149}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":19,"numAtRisk":292},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":289},{"groupId":"EG002","numEvents":9,"numAffected":7,"numAtRisk":159},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":149}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":11,"numAtRisk":292},{"groupId":"EG001","numEvents":14,"numAffected":13,"numAtRisk":289},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":159},{"groupId":"EG003","numEvents":9,"numAffected":9,"numAtRisk":149}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":14,"numAtRisk":292},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":289},{"groupId":"EG002","numEvents":23,"numAffected":21,"numAtRisk":159},{"groupId":"EG003","numEvents":19,"numAffected":14,"numAtRisk":149}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":21,"numAtRisk":292},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":289},{"groupId":"EG002","numEvents":14,"numAffected":11,"numAtRisk":159},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":149}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":49,"numAffected":41,"numAtRisk":292},{"groupId":"EG001","numEvents":18,"numAffected":14,"numAtRisk":289},{"groupId":"EG002","numEvents":26,"numAffected":21,"numAtRisk":159},{"groupId":"EG003","numEvents":22,"numAffected":18,"numAtRisk":149}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":25,"numAtRisk":292},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":289},{"groupId":"EG002","numEvents":30,"numAffected":23,"numAtRisk":159},{"groupId":"EG003","numEvents":13,"numAffected":13,"numAtRisk":149}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":20,"numAtRisk":292},{"groupId":"EG001","numEvents":22,"numAffected":21,"numAtRisk":289},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":159},{"groupId":"EG003","numEvents":16,"numAffected":15,"numAtRisk":149}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":292},{"groupId":"EG001","numEvents":15,"numAffected":15,"numAtRisk":289},{"groupId":"EG002","numEvents":18,"numAffected":16,"numAtRisk":159},{"groupId":"EG003","numEvents":15,"numAffected":13,"numAtRisk":149}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":20,"numAtRisk":292},{"groupId":"EG001","numEvents":18,"numAffected":16,"numAtRisk":289},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":159},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":149}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":17,"numAtRisk":292},{"groupId":"EG001","numEvents":15,"numAffected":13,"numAtRisk":289},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":159},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":149}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":16,"numAtRisk":292},{"groupId":"EG001","numEvents":20,"numAffected":20,"numAtRisk":289},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":159},{"groupId":"EG003","numEvents":9,"numAffected":9,"numAtRisk":149}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":27,"numAtRisk":292},{"groupId":"EG001","numEvents":27,"numAffected":27,"numAtRisk":289},{"groupId":"EG002","numEvents":12,"numAffected":11,"numAtRisk":159},{"groupId":"EG003","numEvents":23,"numAffected":19,"numAtRisk":149}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":50,"numAffected":46,"numAtRisk":292},{"groupId":"EG001","numEvents":46,"numAffected":43,"numAtRisk":289},{"groupId":"EG002","numEvents":31,"numAffected":28,"numAtRisk":159},{"groupId":"EG003","numEvents":24,"numAffected":23,"numAtRisk":149}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":17,"numAtRisk":292},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":289},{"groupId":"EG002","numEvents":7,"numAffected":5,"numAtRisk":159},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":149}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":84,"numAffected":66,"numAtRisk":292},{"groupId":"EG001","numEvents":71,"numAffected":60,"numAtRisk":289},{"groupId":"EG002","numEvents":61,"numAffected":43,"numAtRisk":159},{"groupId":"EG003","numEvents":43,"numAffected":38,"numAtRisk":149}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":32,"numAtRisk":292},{"groupId":"EG001","numEvents":13,"numAffected":11,"numAtRisk":289},{"groupId":"EG002","numEvents":21,"numAffected":19,"numAtRisk":159},{"groupId":"EG003","numEvents":6,"numAffected":5,"numAtRisk":149}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":20,"numAtRisk":292},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":289},{"groupId":"EG002","numEvents":15,"numAffected":10,"numAtRisk":159},{"groupId":"EG003","numEvents":9,"numAffected":8,"numAtRisk":149}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":292},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":289},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":159},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":149}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":20,"numAtRisk":292},{"groupId":"EG001","numEvents":15,"numAffected":13,"numAtRisk":289},{"groupId":"EG002","numEvents":14,"numAffected":12,"numAtRisk":159},{"groupId":"EG003","numEvents":12,"numAffected":11,"numAtRisk":149}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":292},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":289},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":159},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":149}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":17,"numAtRisk":292},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":289},{"groupId":"EG002","numEvents":32,"numAffected":29,"numAtRisk":159},{"groupId":"EG003","numEvents":36,"numAffected":36,"numAtRisk":149}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":444,"numAffected":223,"numAtRisk":292},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":289},{"groupId":"EG002","numEvents":160,"numAffected":100,"numAtRisk":159},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":149}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":70,"numAffected":62,"numAtRisk":292},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":289},{"groupId":"EG002","numEvents":34,"numAffected":27,"numAtRisk":159},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":149}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":12,"numAtRisk":292},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":289},{"groupId":"EG002","numEvents":12,"numAffected":9,"numAtRisk":159},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":149}]},{"term":"Nail disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":17,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":159},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":149}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":30,"numAtRisk":292},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":289},{"groupId":"EG002","numEvents":16,"numAffected":13,"numAtRisk":159},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":149}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":20,"numAtRisk":292},{"groupId":"EG001","numEvents":38,"numAffected":32,"numAtRisk":289},{"groupId":"EG002","numEvents":10,"numAffected":8,"numAtRisk":159},{"groupId":"EG003","numEvents":13,"numAffected":12,"numAtRisk":149}]},{"term":"Skin disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":24,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":17,"numAffected":13,"numAtRisk":159},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":149}]},{"term":"Skin fissures","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":15,"numAtRisk":292},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":289},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":159},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":149}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":29,"numAtRisk":292},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":289},{"groupId":"EG002","numEvents":17,"numAffected":15,"numAtRisk":159},{"groupId":"EG003","numEvents":11,"numAffected":11,"numAtRisk":149}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D012008","term":"Recurrence"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D020969","term":"Disease Attributes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068437","term":"Pemetrexed"},{"id":"D000068818","term":"Cetuximab"},{"id":"D000077143","term":"Docetaxel"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"},{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"}]}},"hasResults":true}